Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792555 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
A Phase 2 study, sponsored by Crinetics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03792555 is a Phase 2 study that has completed, run by Crinetics Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT03792555, a Phase 2 study, has completed, sponsored by Crinetics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.
Interventions
- DRUG Placebo
- DRUG Paltusotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792555
The ClinicalTrials.gov registry entry for NCT03792555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03792555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792555 about?
NCT03792555 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)". A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.
What is the current status of trial NCT03792555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-03-11. Estimated completion is 2020-08-12.
What interventions are being tested in trial NCT03792555?
The interventions under investigation include: Placebo (DRUG), Paltusotine (DRUG).
Who is sponsoring clinical trial NCT03792555?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.